Author: Bozzetti, Silvia; Ferrari, Sergio; Zanzoni, Serena; Alberti, Daniela; Braggio, Michele; Carta, Sara; Piraino, Francesco; Gabbiani, Daniele; Girelli, Domenico; Nocini, Riccardo; Monaco, Salvatore; Crisafulli, Ernesto; Mariotto, Sara
Title: Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? Cord-id: 2iefu5c6 Document date: 2021_8_7
ID: 2iefu5c6
Snippet: The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospital of Verona, Italy between March and June 2020. We analysed serum neurofilament light chain (NfL) levels in all cases including a subgroup (n = 29) of patients with available onset samples. Compariso
Document: The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospital of Verona, Italy between March and June 2020. We analysed serum neurofilament light chain (NfL) levels in all cases including a subgroup (n = 29) of patients with available onset samples. Comparisons between clinical and biomarker data were then performed. Neurological symptoms were still present in a significant number (n = 49) of patients over the follow-up. The most common reported symptoms were hyposmia (n = 11), fatigue (n = 28), myalgia (n = 14), and impaired memory (n = 11) and were more common in cases with severe acute COVID-19. Follow-up serum NfL values (15.2 pg/mL, range 2.4–62.4) were within normal range in all except 5 patients and did not differentiate patients with vs without persistent neurological symptoms. In patients with available onset and follow-up samples, a significant (p < 0.001) decrease of NfL levels was observed and was more evident in patients with a severe acute disease. Despite the common persistence of neurological symptoms, COVID-19 survivors do not show active axonal damage, which seems a peculiar feature of acute SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- acute disease and long term neurological sequelae: 1, 2, 3, 4
- acute disease and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute disease and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- acute event and lung function: 1, 2
- acute phase and long term effect: 1, 2
- acute phase and long term neurological sequelae: 1, 2, 3
- acute phase and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute sars infection and long term neurological sequelae: 1, 2, 3
- acute sars infection and lung capacity: 1, 2, 3, 4, 5, 6, 7, 8
- acute sars infection and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute stage and long term neurological sequelae: 1
- acute stage and lung capacity: 1
- acute stage and lung function: 1, 2
- long term effect and lung function: 1, 2, 3
- long term neurological sequelae and lung function: 1
Co phrase search for related documents, hyperlinks ordered by date